Administration of Trelegy Ellipta to pregnant women should only be considered if the expected benefit to the mother justifies the potential risk to the foetus.
It is unknown whether fluticasone furoate, umeclidinium, vilanterol or their metabolites are excreted in human milk. However, other corticosteroids, muscarinic antagonists and beta2-adrenergic agonists are detected in human milk. A risk to newborns/infants cannot be excluded.
There are no data on the effects of fluticasone furoate/umeclidinium/vilanterol on human fertility.